Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Petra, Vočková"'
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
Autor:
Radek Jakša, Jana Karolová, Michael Svatoň, Dmitry Kazantsev, Martina Grajciarová, Eva Pokorná, Zbyněk Tonar, Magdalena Klánová, Lucie Winkowska, Diana Maláriková, Petra Vočková, Kristina Forsterová, Nicol Renešová, Alexandra Dolníková, Kristýna Nožičková, Pavel Dundr, Eva Froňková, Marek Trněný, Pavel Klener
Publikováno v:
Laboratory Investigation. 102:957-965
Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. Patient-derived xenografts (PDXs) are used for various aspects of translational research including preclinical in vivo validation of experimental treatment approaches. Wh
Autor:
Robert, Pola, Eva, Pokorná, Petra, Vočková, Eliška, Böhmová, Michal, Pechar, Jana, Karolová, Jan, Pankrác, Luděk, Šefc, Karel, Helman, Marek, Trněný, Tomáš, Etrych, Pavel, Klener
Publikováno v:
Acta biomaterialia. 119
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (B-NHL) with chronically relapsing clinical course. Implementation of cytarabine (araC) into induction and salvage regimen became standard of care for majority of MCL patient
Autor:
Peter, Keša, Eva, Pokorná, Martina, Grajciarová, Zbyněk, Tonar, Petra, Vočková, Philippe, Trochet, Milan, Kopeček, Radek, Jakša, Luděk, Šefc, Pavel, Klener
Publikováno v:
Ultrasound in medicinebiology. 47(4)
Tumor oxygenation and vascularization are important parameters that determine the aggressiveness of the tumor and its resistance to cancer therapies. We introduce dual-modality ultrasound and photoacoustic imaging (US-PAI) for the direct, non-invasiv
Autor:
Pavel, Otáhal, Dana, Průková, Vlastimil, Král, Milan, Fabry, Petra, Vočková, Lucie, Latečková, Marek, Trněný, Pavel, Klener
Publikováno v:
Oncoimmunology
Tumor immunotherapy based on the use of chimeric antigen receptor modified T cells (CAR T cells) is a promising approach for the treatment of refractory hematological malignancies. However, a robust response mediated by CAR T cells is observed only i